There is growing recognition that the United States' clinical trials enterprise (CTE) faces great challenges. There is a gap between what is desired - where medical care is provided solely based on high quality evidence - and the reality - where there is limited capacity to generate timely and practical evidence for drug development and to support medical treatment decisions.
With the need for transforming the CTE in the U.S. becoming more pressing, the IOM Forum on Drug Discovery, Development, and Translation held a two-day workshop in November 2011, bringing together leaders in research and health care. The workshop focused on how to transform the CTE and discussed a vision to make the enterprise more efficient, effective, and fully integrated into the health care system. Key issue areas addressed at the workshop included: the development of a robust clinical trials workforce, the alignment of cultural and financial incentives for clinical trials, and the creation of a sustainable infrastructure to support a transformed CTE. This document summarizes the workshop.
Institute of Medicine. 2012. Envisioning a Transformed Clinical Trials Enterprise in the United States: Establishing an Agenda for 2020: Workshop Summary. Washington, DC: The National Academies Press. https://doi.org/10.17226/13345.
|2 Integrating Community Practice and Clinical Trials||13-26|
|3 Improving Public Participation in Clinical Trials||27-42|
|4 Creating a New Business Model for Clinical Trials||43-52|
|5 Building an Infrastructure to Support Clinical Trials||53-62|
|6 Suggesting an Agenda for Transforming Elements of the Clinical Trials Enterprise||63-80|
|Appendix A: Workshop Agenda||85-96|
|Appendix B: Participant Biographies||97-122|
|Appendix C: Registered Workshop Attendees||123-132|
|Appendix D: Discussion Paper: The Clinical Trials Enterprise in the United States: A Call for Disruptive Innovation||133-160|
|Appendix E: Discussion Paper: Developing a Robust Clinical Trials Workforce||161-182|
|Appendix F: Discussion Paper: Transforming the Economics of Clinical Trials||183-192|
|Appendix G: Discussion Paper: Developing a Clinical Trials Infrastructure||193-202|
|Appendix H: Discussion Paper: Canadian Strategy on Patient-Oriented Research||203-206|
|Appendix I: Discussion Paper: Health Research as a Public Good||207-210|
|Appendix J: Discussion Paper: Novel Ways to Get Good Trial Data: The UK Experience||211-224|
|Appendix K: IOM Staff Paper: Context and Glossary of Select Terms Associated with the Clinical Trials Enterprise||225-232|
The Chapter Skim search tool presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter. You may select key terms to highlight them within pages of each chapter.
The National Academies Press (NAP) has partnered with Copyright Clearance Center's Rightslink service to offer you a variety of options for reusing NAP content. Through Rightslink, you may request permission to reprint NAP content in another publication, course pack, secure website, or other media. Rightslink allows you to instantly obtain permission, pay related fees, and print a license directly from the NAP website. The complete terms and conditions of your reuse license can be found in the license agreement that will be made available to you during the online order process. To request permission through Rightslink you are required to create an account by filling out a simple online form. The following list describes license reuses offered by the National Academies Press (NAP) through Rightslink:
Click here to obtain permission for the above reuses. If you have questions or comments concerning the Rightslink service, please contact:
Rightslink Customer Care
Tel (toll free): 877/622-5543
To request permission to distribute a PDF, please contact our Customer Service Department at 800-624-6242 for pricing.
To request permission to translate a book published by the National Academies Press or its imprint, the Joseph Henry Press, pleaseclick here to view more information.